Candesartan cilexetil

Drug Profile

Candesartan cilexetil

Alternative Names: Amias; Atacand; Blopress; Candesartan hexetil; Kenzen; Parapres; Ratacand; TCV-116; Tiadyl

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Netherlands Cancer Institute; Takeda
  • Class Antihypertensives; Benzimidazoles; Heart failure therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • No development reported Cardiovascular disorders
  • Discontinued Coronary artery restenosis; Diabetic nephropathies; Diabetic retinopathy; Glomerulonephritis

Most Recent Events

  • 16 Jun 2017 Updated efficacy data from the TROPHY trial in Hypertension presented at the 27th European Meeting on Hypertension and Cardiovascular Protection
  • 15 Mar 2016 Biomarkers information updated
  • 23 May 2013 Generic equivalent available in USA for Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top